In the mammary gland, the stromal extracellular matrix (ECM) undergoes dramatic changes during development and in tumorigenesis. For example, normal adult breast tissue is largely devoid of the ECM protein fibronectin (FN) whereas high FN levels have been detected in the stroma of breast tumors. FN is an established marker for epithelial-mesenchymal transition (EMT), which occurs during development and has been linked to cancer. During EMT, epithelial cell adhesion switches from cell-cell contacts to mainly cell-ECM interactions, raising the possibility that FN may have a role in promoting this transition. Using MCF-10A mammary epithelial cells, we show that exposure to exogenous FN induces an EMT response including upregulation of the EMT markers FN, Snail, N-cadherin, vimentin, the matrix metalloprotease MMP2, a-smooth muscle actin and phospho-Smad2, as well as acquisition of cell migratory behavior. FN-induced EMT depends on Src kinase and extracellular signal-regulated kinase/mitogen-activated protein (ERK/MAP) kinase signaling but not on the immediate early gene EGR-1. FN initiates EMT under serum-free conditions; this response is partially reversed by a transforming growth factor (TGF)b-neutralizing antibody, suggesting that FN enhances the effect of endogenous TGFb. EMT marker expression is upregulated in cells on a fragment of FN containing the integrin-binding domain but not other domains. Differences in gene expression between FN and Matrigel are maintained with addition of a subthreshold level of TGFb1. Together, these results show that cells interacting with FN are primed to respond to TGFb. The ability of FN to induce EMT shows an active role for the stromal ECM in this process and supports the notion that the increased levels of FN observed in breast tumors facilitate tumorigenesis.
INTRODUCTION
The extracellular matrix (ECM) is a key component of a cell's microenvironment and cooperates with other extracellular molecules to relay external signals into cells. Many studies have implicated the ECM in various aspects of mammary gland development and breast cancer. [1] [2] [3] The laminin-rich basement membrane is critical for mammary morphogenesis and secretion of milk proteins. [4] [5] [6] [7] The stromal ECM protein fibronectin (FN) is essentially absent from normal adult breast tissue whereas increased FN messenger RNA (mRNA) and protein levels have been detected in the stroma of breast tumors. [8] [9] [10] [11] [12] In fact, FN levels in breast tumor tissues are positively correlated with tumor malignancy and negatively correlated with the survival rate of breast cancer patients, 9, 10, 13 suggesting that FN might have a role in cancer progression and/or severity. FN transmits ECM signals by binding to integrin receptors, which are heterodimeric transmembrane proteins that link the ECM with the cytoskeleton and intracellular signaling pathways. 14 Like FN, b1 integrin levels are also associated with decreased survival in invasive breast cancer. 13 How higher levels of FN in breast tumors contribute to tumorigenesis is not understood. In three-dimensional cell cultures on a Matrigel (MG)-reconstituted basement membrane, mammary epithelial cells develop into acini similar to in vivo structures with a layer of polarized cells surrounding a hollow lumen and supported by a laminin-rich matrix. 15, 16 Addition of FN to polarized, growth-arrested mammary acini stimulates cell proliferation and turns on FN expression, 17 and exposure of T4-2 tumorigenic cells to anti-FN antibodies promotes a polarized acinar organization similar to that of normal breast epithelial cells in three-dimensional culture. 18 These observations suggest that FN levels might have a role during tumor formation.
Epithelial-mesenchymal transition (EMT) is a process in which epithelial cells lose apical-basal polarity and cell-to-cell contacts and gain a mesenchymal phenotype, including increased cell-to-ECM contacts and cell migration. 19, 20 EMT decreases expression of epithelial marker genes such as E-cadherin and increases expression of mesenchymal marker genes, such as FN, Snail, N-cadherin, vimentin and the matrix metalloprotease MMP2. During the transition, cells go through an intermediate phase of EMT in which both epithelial and mesenchymal characteristics are present. 20, 21 Although transforming growth factor (TGF)b is a wellknown inducer of EMT, 22 the contributions of the ECM, including FN upregulation, to this process are not understood.
We show that interactions of MCF-10A human mammary epithelial cells with FN induce an EMT response, with upregulation of EMT markers and increased cell migratory behavior. FN contributes to the development of EMT through cooperation with signals initiated by the type-I TGFb receptor. Our findings show an inductive role for FN in EMT and provide a link between changes in ECM composition and tumor progression. secreted into the culture medium and not assembled into a matrix (not shown). FN expression is downregulated during acinar morphogenesis by these cells in three-dimensional MG culture 17 or when grown on a surface coated with MG ( Figure 1a ), indicating that MG represses FN expression. We investigated the modulation of FN expression by performing a time course analysis of FN mRNA and protein expression. FN expression was first downregulated by growth of MCF-10A cells on MG for 2 days. Cells were then replated on surfaces coated with 20 mg/ml solutions of either MG or plasma FN, and expression levels were measured at increasing times after plating. Quantitative reverse transcriptase-PCR analyses show a time-dependent increase in FN mRNA on FN substrate but no significant increase on MG ( Figure 1b ). Sustained upregulation of FN mRNA was observed at 6 h and later but we also detected a transient increase after 2 h. This upregulation of FN mRNA on FN substrate was maintained for at least 4 days ( Figure 1c ). Levels of secreted FN increased subsequently to the initial mRNA upregulation, as detected in the culture medium of cells grown on FN for X4 h (Figure 1d and not shown). Similar changes in FN mRNA upregulation were observed when cells were replated onto a substrate of recombinant FN isolated from insect cells grown in serum-free conditions (Sechler et al. 23 not shown). Together, these results show that MCF-10A cell interactions with FN induce upregulation of FN mRNA and protein expression.
Fibronectin promotes an EMT response Cells undergoing EMT lose epithelial characteristics and show changes in cell adhesion, polarity and gene expression. FN itself is a well-known EMT marker, 24 which suggests that FN-dependent FN upregulation might be part of an EMT response. Expression of other EMT markers was measured after replating cells onto MG or FN. The fold difference between mRNA levels in cells grown on FN compared with cells on MG is shown in Table 1 . MCF-10A cells show significantly increased expression of the EMT markers N-cadherin, Snail, vimentin and matrix metalloproteinase MMP2, after 24 h on FN relative to MG. This upregulation is sustained for at least 4 days (Figure 2a and Supplementary Figures S1A-C). Levels of MMP3 and MMP9 mRNAs (not shown) and a-smooth muscle actin protein (Supplementary Figure S1D ) were also higher on FN than on MG after 2 days.
Upregulation of EMT marker gene expression is dependent on integrin binding to FN. Increases in FN, Snail and N-cadherin mRNAs were comparable between cells on FN and cells plated on a B20 kDa cell-binding domain fragment of FN (GST-III 9-10 ) containing the RGD sequence in III 10 and the synergy site in III 9 (Supplementary Figure S2 ). Therefore, MCF-10A cell adhesion to this integrin-binding domain in the absence of other domains of FN is sufficient to induce changes in gene expression.
A sustained increase in N-cadherin mRNA was accompanied by higher N-cadherin protein levels detected on immunoblots of whole-cell lysates ( Figure 2b ). Immunofluorescence staining of MCF-10A cells also showed higher N-cadherin in cells grown on FN (Figure 2c and Supplementary Figure S3 ). N-cadherin appears more peripherally localized in cells on FN than on MG. These data illustrate a significant substrate-dependent difference in EMT marker expression by MCF-10A cells, and support the conclusion that cell-FN interactions contribute to development of an EMT phenotype.
EMT leads to changes in cell behavior including increased migration. To see whether exposure to FN elicits this response, MCF-10A cells were tested for migration on MG-coated Transwell filters (BD Biosciences, San Jose, CA, USA). After 8 h, more of the Fibronectin stimulates EMT J Park and JE Schwarzbauer cells that had been primed by growth on FN migrated relative to cells that were primed on MG (Figure 3 ), indicating that in addition to marker expression, growth on FN promotes development of a migratory cell behavior.
EMT depends on ERK activation but not EGR-1 upregulation
The early growth response-1 (EGR-1) is an immediate early gene transcription factor whose expression and activity are stimulated by ERK/MAP kinase signaling. 25 This transcription factor has been shown to stimulate FN expression in melanoma cells 26 and to mediate Snail expression in HepG2 cells. 27 We found that plating MCF-10A cells on FN transiently increased EGR-1 mRNA and protein levels in the whole cells and in the nuclear fraction (not shown). Also, it was previously reported that ERK2 overexpression increases levels of N-cadherin and FN in MCF-10A cells. 28 To determine whether ERK and EGR-1 are required for the upregulation of FN and other EMT markers, we inhibited activation of ERK with the MAP kinase kinase inhibitor PD98059. Phospho-ERK1/2 levels on FN were significantly reduced by the inhibitor (Figure 4a ), and this treatment decreased EGR-1 mRNA levels by 65-70% after 1 h on MG or FN (Figure 4b ), confirming a requirement for ERK signaling in EGR-1 upregulation. ERK is rapidly activated in response to extracellular signals, so phospho-ERK levels were monitored within 1-2 h. As changes in gene expression occur downstream of ERK activation, we analyzed EMT markers at 6 h, the earliest time when changes were detected, and at 24 h when marker upregulation appears to peak. Neither Snail nor N-cadherin mRNA was significantly changed by PD98059 treatment for 6 h (Figure 4c and not shown). In contrast, we observed a statistically significant increase in FN mRNA after 6 h of PD98059 treatment on FN (Figure 4d ), suggesting the ERK1/ 2 might be involved in reducing the level of FN production. EGR-1 siRNA treatment reduced its mRNA by 47%, but did not cause a significant change in Snail or FN mRNA levels after 6 or 24 h on FN (not shown). Therefore, EGR-1 is not a critical component of the EMT pathway in MCF-10A cells on a FN substrate. In contrast, ERK activity appears to be involved in this EMT response such that inhibition of this pathway releases negative control on the level of FN expression.
Type-I TGFb receptor activity is required for FN induction of EMT markers
It is well established that TGFb1 induces EMT in MCF-10A and other cells. 22, [29] [30] [31] [32] MCF-10A cell assay medium contains 2% serum, which includes some TGFb1. It is possible that the effects of FN on EMT occur through cooperation between FN and TGFb signaling pathways. Binding of TGFb1 to its receptor stimulates phosphorylation of Smads, and our analysis of Smad2 showed an increase in phosphorylation on FN compared with MG after 1, 2 (Figures 5b and c) . These results show a role for TGFb signaling through phosphorylation of Smad2 in the FN-dependent induction of EMT. We also tested the effects of substrate on TGFb1 expression and found no difference in its mRNA levels between MG and FN (not shown).
A role for a Src pathway in EMT FN integrin binding rapidly activates focal adhesion kinase (FAK) by phosphorylation on Tyr397, and this leads to recruitment of Src 33 and signaling through a FAK/Src complex. 34 Enhanced phospho-FAK was observed in MCF-10A cells plated on FN for 30 min compared with cells on MG (Figure 6a ). To determine whether Src activity affects Smad, cells on either FN or MG were treated with 10 mM SU6656, a Src kinase inhibitor. The pSmad2 level was reduced by as much as 45% with SU6656 ( Figure 6b ). Upregulation of the EMT markers FN, Snail and N-cadherin on a FN substrate was abolished by SU6656 treatment, whereas ubiquitin C mRNA levels and marker levels on MG (except Snail) did not change (Figure 6c ). Therefore, Src activity is required for FN stimulation of its own expression and for induction of other EMT markers in cells on FN, but not MG. Together, these data suggest that Src might have a general effect on Smad2 phosphorylation by type-I TGFb receptor, but that it has a substrate-specific role in regulating EMT marker expression on FN.
Effects of FN or MG in the absence of serum
To determine whether the substrate has a role in EMT, we monitored Smad phosphorylation and expression of EMT markers in the absence of serum. Smad2 was activated in MCF-10A cells on FN but not on MG (Figure 7a ). FN also upregulated expression of FN, Snail and N-cadherin mRNAs in the absence of serum (Figure 7b) , indicating that the substrate promotes an EMT response. Addition of 2% serum, which contains some TGFb, increased pSmad2 on both substrates although levels remained higher on FN (Figure 7a ). pSmad2 levels were similar on MG and FN with the addition of 0.05 ng/ml TGFb1. These results suggest that FN contributes to Smad2 activation and EMT marker induction independently of added TGFb.
To determine whether endogenously produced TGFb was contributing to increased pSmad2 on the FN substrate, cells grown on FN or MG in the absence of serum were treated with a TGFb-neutralizing antibody, and pSmad2 levels were monitored. Untreated cells on FN had a 6.2-fold higher pSmad2 level than cells on MG (Figure 8a ). Antibody treatment reduced pSmad2 on both FN and MG. Although the level in cells on MG decreased almost to 0, pSmad2 remained threefold higher in cells on FN than in untreated cells on MG. Addition of 0.05 ng/ml TGFb significantly increased pSmad2 to similar levels on FN and MG (B12-and 14fold, respectively) and also increased total Smad levels. In spite of Fibronectin stimulates EMT J Park and JE Schwarzbauer equivalent pSmad2 levels, the difference in FN expression between FN and MG substrates was maintained ( Figure 8b) . Interestingly, neutralizing antibody reduced the upregulation on both FN and MG to levels similar to those in cells without added TGFb with more than threefold higher pSmad2 in cells on FN than in untreated cells on MG (Figure 8a ). Using quantitative reverse transcriptase-PCR, we confirmed that the effects of neutralizing antibody on FN expression correlate with changes in pSmad2 (Figure 8b) . These results show that endogenous TGFb and the FN substrate together are responsible for the observed increases in pSmad2.
Cooperation between FN and TGFb in EMT
Differences in cell response on MG versus FN substrate along with results from treatment with the TGFb-neutralizing antibody show that the levels of Smad2 phosphorylation and FN expression are influenced by both FN and TGFb. When TGFb was present in a sufficient amount (X0.05 ng/ml) and for a sufficient time (X6 h), the effects of the FN substrate were not detectable. However, when the level of TGFb was low (such as under serum-free or 2% serum conditions), there was a significant enhancement of pSmad2 levels (Figures 7a and 9a ) and expression of FN and other EMT markers in cells on FN, but not on MG (see Figure 7b ).
To show that interactions with the substrate contribute to the EMT response by TGFb, we used cells grown on FN or MG for 4 h at which time FN mRNA levels are the same on the two substrates. Culture for 4 h with 0.05 ng/ml TGFb1 did not change FN expression levels on MG, but it did increase FN mRNAs about twofold in cells on FN (Figure 9b ). Therefore, cells interacting with FN are primed to respond to TGFb, such that addition of a subthreshold level of TGFb1, which does not stimulate cells on MG, significantly increases FN expression on a FN substrate.
DISCUSSION
In the stroma of normal, fully developed mammary tissue, very little FN is detected. In mammary tumors, on the other hand, an increased stromal FN level correlates with the severity of the disease. 9, 10 In three-dimensional culture, FN stimulates proliferation of growth-arrested polarized mammary epithelial cells, disturbing the hollow acinar structure and promoting tumorlike behavior. 17 The results presented here show that mammary epithelial cell-FN interactions induce an EMT response that includes upregulation of FN, Snail and other EMT markers, as well as increased migratory behavior and activation of Smad2. This induction is substrate specific, occurring on FN and on the cellbinding domain of FN but not on MG. Indeed, increases in EMT marker expression and Smad2 phosphorylation occur in cells on (a) Phospho-Smad2 and total Smad2 levels were detected in cell lysates at 2 h after plating in medium containing 2% serum ± the indicated concentrations of TGFb1. Phospho-Smad2, total Smad2/3 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibodies were used in immunoblots. Band intensities of pSmad2 or total Smad2 relative to GAPDH are indicated below the blot. (b) MCF-10A cells were plated in medium containing 2% serum plus the indicated concentrations of TGFb1. RNA was isolated at 4 h and FN mRNA levels were measured using quantitative reverse transcriptase-PCR (qRT-PCR). Mean ± s.e. for three independent experiments. The mean fold change on FN versus MG was not statistically significant with 0.05 ng/ml TGFb1, but significant with 0.1 ng/ml TGFb1 (Po0.05).
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FN under serum-free conditions, and a TGFb-neutralizing antibody reduced but did not eliminate pSmad2 in cells on FN, demonstrating that substrate composition has an inductive effect on EMT. Addition of TGFb1 enhances the effects of FN on EMT and our results suggest that interactions with FN, but not with MG, prime cells to respond to growth factor stimulation. Together, our findings suggest that stromal FN alone can induce an EMT response, and that the cooperative action of stromal FN with TGFb may promote epithelial cell changes during EMT and tumorigenesis.
Tumor formation in the breast involves changes in mammary epithelial cell interactions with the ECM. Loss of basement membrane integrity is a hallmark of cancer and occurs through changes in expression of ECM proteins or their receptors and through increased release of matrix metalloproteases. 35 Basement membrane breach exposes epithelial cells to the stromal ECM, and our results support the idea that cell-stromal interactions have a synergistic role in promoting a change in cell phenotype such as EMT. Upregulation of FN expression by cancer-associated fibroblasts 36 or transport into the tissue of FN, which can be increased in the plasma in breast cancer, 37 are two ways in which stromal FN levels could be elevated. Our results showing cell stimulation by FN when levels of TGFb are subthreshold indicate that an upregulation of FN in tissue could impact the rate of tumor formation.
Stimulation of MCF-10A cells growing on FN with a low level of TGFb1 significantly increased FN expression, but did not have the same effect when cells were on MG. This observation raises the possibility that in vivo epithelial cells attached to a basement membrane respond to this growth factor differently than cells in contact with the stromal ECM. Furthermore, the response of MCF-10A cells may depend on the concentration of TGFb in the stroma such that low levels of growth factor in a FN-rich stroma might induce EMT, while these levels of TGFb are below the threshold needed to have an effect on cells in contact with a basement membrane. Our results showing that EMT markers were upregulated in cells on the III 9-10 integrin-binding domain of FN suggest that intracellular signaling from FN through integrins cooperates with TGFb1 signaling to induce FN gene expression. The possibility that TGFb and FN cooperate through direct interactions seems less likely as TGFb has been shown to bind to FN's III [12] [13] [14] heparinbinding domain. 38 There also may be a temporal component to the substrate effects as observed for Snail expression, which is directly downstream of Smad signaling. 39 Under low TGFb conditions at 4 h where FN expression is equivalent on FN and MG substrates, Snail expression was significantly higher on FN (JP, unpublished observations). However, upregulation of FN and Snail both involve Src activity, suggesting that a pathway downstream of Src cooperates with a pathway initiated by pSmad2 to increase expression of EMT markers. In vivo it is possible that TGFb1 and FN might help each other to promote the induction of EMT responses in the cells to exacerbate cancer formation.
In addition to expression of EMT markers, cell-FN interactions also enhanced cell migratory behavior, which is another important characteristic of EMT. Although cells grown on FN showed upregulation of mesenchymal markers and increased cell motility, we did not observe a decrease in the epithelial marker E-cadherin. N-cadherin can promote cell motility in breast cancer cells regardless of E-cadherin expression, 40 and others have proposed that the ratio of N-cadherin to E-cadherin determines the EMT phenotype. 21 Treatment of MCF-10A cells with 5 ng/ml TGFb1 for 2 days induced dramatic increases in FN, Snail and N-cadherin mRNAs (63-, 35-and 16-fold, respectively) but did not significantly change E-cadherin expression (JP, unpublished observations). Furthermore, in other reports, these cells showed modest changes at best in E-cadherin levels with extended TGFb treatment, [41] [42] [43] indicating that EMT in MCF-10A cells does not include robust changes in E-cadherin. Furthermore, decreased E-cadherin might not be a major phenotype of breast cancer development; Goyal et al. 44 reported no difference in E-cadherin expression between tumor and normal breast tissue. It is also possible that cells on FN might be in an intermediate phase of EMT in which some characteristics of both epithelial and mesenchymal phenotypes are present, and upregulation of N-cadherin without downregulation of E-cadherin is sufficient to increase cell motility.
FN binding to integrins activates a number of intracellular pathways that synergize with signals from various growth factors. 45 We have shown that together FN and TGFb enhance the induction of an EMT response in mammary epithelial cells. We propose that increased FN in breast cancer might be both a cause and a result of tumor initiation and/or progression. Therefore, modulating FN expression might present a new way to control tumor formation.
MATERIALS AND METHODS
Cell culture MCF-10A cells were purchased from the American Type Culture Collection and cultured as previously described. 46 Cells were cultured for no more than 25 passages. When passaged, cells were grown in growth medium containing 5% horse serum (Invitrogen, Grand Island, NY, USA), 20 ng/ml EGF (Peprotech, Rocky Hill, NJ, USA), 0.5 mg/ml hydrocortisone (Sigma, St Louis, MO, USA), 100 ng/ml cholera toxin (Sigma), 10 mg/ml insulin (Sigma) and penicillin/streptomycin (Invitrogen) in Dulbecco's modified Eagle medium/F12 (Invitrogen). For experiments, cells were plated in assay medium containing 2% horse serum (Invitrogen), 5 ng/ml EGF (Peprotech), 0.5 mg/ml hydrocortisone (Sigma), 100 ng/ml cholera toxin (Sigma), 10 mg/ ml insulin (Sigma) and penicillin/streptomycin (Invitrogen) in Dulbecco's modified Eagle medium/F12 (Invitrogen), unless specified otherwise. To coat the surface, tissue culture dishes were incubated with 20 mg/ml rat plasma FN or 20 mg/ml Matrigel (BD Biosciences) in phosphate-buffered saline at 4 1C overnight. Rat plasma FN was purified from rat plasma (Taconic, Hudson, NY, USA) by gelatin-sepharose affinity chromatography, as previously described. 47 TGFb1 was purchased from R&D systems (Minneapolis, MN, USA).
For comparison of cell behaviors on MG and FN, MCF-10A cells were first grown on a MG substrate for 2 days to reduce FN expression, and then replated on MG or FN to be grown for various times before analysis. When an inhibitor was used, the cells grown on MG for 2 days were resuspended in assay medium containing the inhibitor and incubated for at least 10min before being replated on MG or FN. The following inhibitors were used: type-I TGFb receptor inhibitor (Calbiochem, Billerica, MA, USA), PD98059 (Enzo Lifesciences, Farmingdale, NY, USA) and SU6656 (Calbiochem). The TGFb-neutralizing antibody (clone 1D11, R&D Systems) was added to cells suspended in serum-free assay medium at the time of replating on MG or FN.
Quantitative reverse transcriptase-PCR
After various incubation times, RNA was extracted using Qiagen (Germantown, MD, USA) RNeasy mini kit following the manufacturer's instructions. complementary DNA was prepared with 0.5 mg RNA per 20 ml reaction volume, 0.5 mM deoxyribonucleotide triphosphate, 2.5 mM random hexamer, 10 mM dithiothreitol and SuperScript II Reverse Transcriptase and buffer (Invitrogen). Real-time PCR was performed using Stratagene (Santa Clara, CA, USA) Mx3000P, following the manufacturer's instructions. Glyceraldehyde 3-phosphate dehydrogenase primers were used as a normalization control. To calculate mRNA fold change for a particular gene of interest, the mRNA level for each complementary DNA sample was normalized to the glyceraldehyde 3-phosphate dehydrogenase mRNA level. The normalized value from cells on MG was set to one for the indicated time point, and all other mRNA levels in the cells on FN or with other treatments were calculated relative to the MG standard for the same time point. If multiple time points were being compared, the normalized value from cells on MG for the shortest time point was set to one. Values from at least three experiments were averaged and s.e. was calculated unless indicated otherwise.
Primer design
All primers were designed using MacVector (MacVector, Inc., Cary, NC, USA) with parameters for real-time PCR. Each primer in a pair was selected from two different exons to distinguish complementary DNA product from genomic DNA amplification. Products were confirmed by PAGE. The primer sequences are as follows: glyceraldehyde 3-phosphate dehydrogenase: forward primer 5 0 -TGA CAACTTTGGTATCGTGGAAGG-3 0 reverse primer 5 0 -AGGGATGATGTTCTGGAGAGCC-3 0 FN: forward primer 5 0 -TGAAAGACCAGCAGAGGCATAAG-3 0 reverse primer 5 0 -CTCATCTCCAACGGCATAATGG-3 0 Snail: forward primer 5 0 -ATCGGAAGCCTAACTACAGCGAGC-3 0 reverse primer 5 0 -CAGAGTCCCAGATGAGCATTGG-3 0 N-cadherin: forward primer 5 0 -ACCAGGTTTGGAATGGGACAG-3 0 reverse primer 5 0 -ATGTTGGGTGAAGGGGTGCTTG-3 0 Vimentin: forward primer 5 0 -TGAAGGAGGAAATGGCTCGTC-3 0 reverse primer 5 0 -GTTTGGAAGAGGCAGAGAAATCC-3 0 MMP2: forward primer 5 0 -CCAACTACAACTTCTTCCCTCGC-3 0 reverse primer 5 0 -GCAAAGGCATCATCCACTGTCTC-3 0 ubiquitin C: forward primer 5 0 -ATTTGGGTCGCGGTTCTT-3 0 reverse primer 5 0 -TGCCTTGACATTCTCGATGGT-3 0 EGR-1: forward primer 5 0 -CAGCAGCACCTTCAACCCTCAG-3 0 reverse primer 5 0 -AGTGGTTTGGCTGGGGTAACTG-3 0 TGFb1: forward primer 5 0 -ATTCCTGGCGATACCTCAGC-3 0 reverse primer 5 0 -ACCCGTTGATGTCCACTTGC-3 0 Type-I TGFb receptor: forward primer 5 0 -ATTCCTGGCGATACCTCAGC-3 0 reverse primer 5 0 -ACCCGTTGATGTCCACTTGC-3 0 In order to verify whether each primer set makes a correct product, the quantitative reverse transcriptase sample was run in 6% polyacrylamide gel, and only one band in the correct size was visible with ethidium bromide under ultraviolet illumination.
Immunoblots
Cells were lysed with modified radioimmunoprecipitation assay buffer (50 mM hydroxyethyl piperazineethanesulfonic acid pH 7.5, 1.5 mM MgCl 2 , 1% Triton X-100, 150 mM NaCl, 0.1% SDS, 1% deoxycholic acid, 1 mM EGTA, 1 mM Na 3 VO 4 , 10 mM Na 4 P 2 O 7 , 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml aprotinin and 10 ng/ml leupeptin) to isolate total proteins from the whole cells, and a BCA assay (Thermo Scientific, Waltham, MA, USA) was performed to determine the concentrations. To extract secreted FN, the medium from equivalent numbers of cells grown on MG or FN was incubated with gelatin-sepharose beads, and the FN was eluted by boiling the beads in electrophoresis sample buffer for 2 min. Equal proportions were resolved by 5% SDS-PAGE for FN and 10% SDS-PAGE for the other proteins, and were transferred to nitrocellulose membrane. Anti-human FN monoclonal antibody HFN 7.1 culture supernatant (1:10 000, Developmental Studies Hybridoma Bank, Iowa City, IA, USA) was used to detect human FN that was secreted by the MCF-10A cells. HFN7.1 is speciesspecific and does not recognize mouse FN. 48 Other antibodies and dilutions used include: EGR-1 (1:5000, Santa Cruz, Dallas, TX, USA), phospho-ERK1/2 (1:5000, Sigma), total ERK1/2 (1:1000, Cell Signaling, Danvers, MA, USA), phospho-FAK(Y397; 1:2000, Invitrogen), total FAK (1:1000, Millipore, Billerica, MA, USA), phospho-Smad2 (1:1000, Cell Signaling), total Smad 2/3 (1:1000, Cell Signaling), N-cadherin (1:20, 13A9, a gift from Keith R Johnson, University of Nebraska Medical Center) and a-smooth muscle actin (1:2000, Sigma). Antibody binding was detected using SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific). Band intensities were quantified using ImageJ Gel analysis tool (National Institutes of Health, Bethesda, MD, USA). Total band intensities were determined from multiple exposures in the linear range of exposure for each antibody. The total intensity of glyceraldehyde 3phosphate dehydrogenase was used for normalization.
Transwell cell migration assay
Cells grown on MG or FN for 2 days were trypsinized and resuspended in assay medium without serum. 5 Â 10 4 cells were plated on a transwell polycarbonate membrane with 8 mM pores (BD BioCoat, San Jose, CA, USA), which was placed in a 24-well dish containing assay medium with 2% horse serum. After 8 h, cells on top of the filter were removed with a cotton swab and the cells that had migrated to the bottom of the filter were fixed and stained with 4 0 ,6-diamidino-2-phenylindole and migrated cells were counted in multiple microscope fields.
Immunofluorescence
Immunofluorescence staining of cells was done as described. 46 Cells grown on MG or FN-coated coverslips for 3 days were fixed, permeabilized and stained with anti-N-cadherin (Invitrogen) antibodies in 1% bovine serum albumin/phosphate-buffered saline, followed by Alexa Fluor goat anti-mouse IgG (Molecular Probes, Grand Island, NY, USA) and 4 0 ,6diamidino-2-phenylindole (Sigma-Aldrich, St Louis, MO, USA). Images were acquired and normalized using iVision software (BioVision Technologies, Exton, PA, USA).
